Evidence map›Paper›PMID 34540318›Full record

ArticleJournal of pharmaceutical analysis2021

COVID-19 vaccine candidates and vaccine development platforms available worldwide.

Nilgun Duman, Zahraa ALzaidi, Busra Aynekin, Duygu Taskin, Busra Demirors, Abdulbaki Yildirim, Izem Olcay Sahin, Faik Bilgili, Eda Tahir Turanli, Tommaso Beccari and 2 more

Abstract read
In one paragraph

Article in Journal of pharmaceutical analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Promising Antiviral Activity ofPharmaceuticals (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nilgun DumanDepartment of Medical Genetics, Dragos Hospital Istanbul, Bezmialem Vakif University, Istanbul, 34854, Turkey.
Zahraa ALzaidiDepartment of Biotechnology, Faculty of Applied Science, Cukurova University, Adana, 01380, Turkey.
Busra AynekinDepartment of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey.
Duygu TaskinDepartment of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey.
Busra DemirorsDepartment of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey.
Abdulbaki YildirimDepartment of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey.
Izem Olcay SahinDepartment of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey.
Faik BilgiliDepartment of Economics, Faculty of Economics and Administrative Sciences, Erciyes University, Kayseri, 38030, Turkey.
Eda Tahir TuranliDepartment of Molecular Biology and Genetics, Faculty of Science, Acibadem University, 34684, Istanbul, Turkey.
Tommaso BeccariDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, 06123, Italy.
Matteo BertelliMAGI'S LAB, Rovereto (TN), Trentino, 38068, Italy.
Munis DundarDepartment of Medical Genetics, Medical Faculty, Erciyes University, Kayseri, 38030, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development.

Indexed as

Coronavirus outbreakCOVID-19 vaccineSARS-CoV-2 variantsTreatmentVaccine development platform

Identifiers

PMID34540318
PMCPMC8437828

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.